1. Rational design, molecular docking and synthesis of novel homopiperazine linked imidazo[1,2-a]pyrimidine derivatives as potent cytotoxic and antimicrobial agents
- Author
-
Rambabu Gundla, Manohar Mantipally, Santhosh Reddy Mandha, Venkatanarayana Chowdary Maddipati, Madhusudhana Reddy Gangireddy, and Vishnu Nayak Badavath
- Subjects
Antifungal Agents ,Pyrimidine ,Stereochemistry ,Clinical Biochemistry ,Pharmaceutical Science ,Antineoplastic Agents ,Microbial Sensitivity Tests ,Gram-Positive Bacteria ,01 natural sciences ,Biochemistry ,HeLa ,Structure-Activity Relationship ,chemistry.chemical_compound ,DU145 ,Gram-Negative Bacteria ,Drug Discovery ,Humans ,MTT assay ,Cytotoxicity ,Piperazine ,Molecular Biology ,Cell Proliferation ,chemistry.chemical_classification ,Dose-Response Relationship, Drug ,Molecular Structure ,biology ,010405 organic chemistry ,Organic Chemistry ,Fungi ,Active site ,Antimicrobial ,biology.organism_classification ,Anti-Bacterial Agents ,0104 chemical sciences ,Molecular Docking Simulation ,010404 medicinal & biomolecular chemistry ,Pyrimidines ,Enzyme ,chemistry ,A549 Cells ,Drug Design ,biology.protein ,Molecular Medicine ,Drug Screening Assays, Antitumor ,HeLa Cells - Abstract
Designed and synthesized novel homopiperazine linked imidazo[1,2- a ]pyrimidine derivatives ( 10a–i , 11a–g , 12 ), and evaluated them for their in vitro cytotoxicity against HeLa cells (cervical cancer), A549 cells (lung cancer) cells, by MTT assay. Compound 12 (IC 50 = 4.14 µM) and compound 10c (IC 50 = 5.98 µM) were found to be 2.5 fold, and 1.74 fold more potent when compared with standard Etoposide (IC 50 = 10.44 µM), against A549 (lung cancer cells). Compound 12 also found to be 1.57 and 1.13 fold potent against DU145 (IC 50 = 6.24 µM) and HeLa (IC 50 = 6.54 µM), respectively when compared with Etoposide (DU145, IC 50 = 9.8 µM; HeLa, IC 50 = 7.43 µM). Compound 10f (IC 50 = 6.12 µM) was found to be 1.31 fold more potent than Etoposide (IC 50 = 7.43 µM) against HeLa cell lines. Moreover compounds 10a and 11a showed cytotoxicity at low micro-molar concentrations against A549 cells. Synthesized compounds were also evaluated for their antimicrobial activity by Cup plate diffusion method. Compounds 10c , 11b , 11d and 11f displayed remarkable antimicrobial activity relating to their standard drugs Gentamycin, Amphotericin B and Ampicillin. Significantly, compound 10c showed broad spectrum activity against tested microbial strains. All the designed compounds were well occupied the binding site of the colchicine and interacted with both α- and β -tubuline interface (PDB ID: 3E22 ), which demonstrates that synthesized compounds are promising tubulin inhibitors. Also, the synthesized compounds occupied the catalytic triad and adenine-binding site, in the active site of β -ketoacyl-acyl carrier protein synthase III enzyme (PDB ID: 1MZS ). The molecular docking results provided the useful information for the future design of more potent inhibitors. These preliminary results convinced further investigation and modifications on synthesized compounds aiming towards the development of potential cytotoxic as well as antimicrobial agents.
- Published
- 2019
- Full Text
- View/download PDF